Real-world evidence (RWE) is one of the fastest ways to strengthen credibility in digital health, especially when you have access to existing datasets. But not every question can be answered retrospectively.
Retrospective data tends to be strong when your goal is to:
Retrospective data tends to be weaker when your solution changes behavior or clinical decisions in a way that must be measured prospectively. For example, if your product aims to change patient management, the strongest proof often requires a design that captures causal impact, not only correlation.
A practical decision rule is:
If your next stakeholder decision depends on demonstrating impact under real use, you likely need a prospective pilot.
If your next decision is funding readiness, partner interest, feasibility, or risk reduction, retrospective analysis may be enough as a first step.
The key is to avoid treating RWE as a generic checkbox. Good RWE starts with a clear claim, a target population, and an endpoint that matters to the decision maker. Then you assess data quality, bias risk, and interpretability.
Worthmed® helps teams use RWE as a structured proof tool, not as an afterthought, and connect the results directly to go-to-market and next-stage pilots.